Chronic graft-versus-host disease (cGVHD) is a frequent complication of allogeneic bone marrow transplantation (BMT). Thalidomide was found to have immunosuppressive properties and it has been used in a limited number of children with cGVHD. We report our experience with refractory and/or high-risk cGVHD in 14 children. Six children showed complete clinical response to thalidomide in a median time of 2 months. Four children had partial responses and four failed. Side-effects were usually mild (somnolence, constipation) and only two patients developed sensory peripheral neuropathy. An increased incidence of infectious complications attributable to thalidomide was not observed. Nine out of 10 responding patients are alive 49-111 months post-BMT. Thalidomide can be effective particularly in children with prevailing mucocutaneous cGVHD. All patients should be carefully monitored to detect peripheral neuropathy early.
1
Chronic GVHD (cGVHD) occurs in 30-60% of all patients surviving Ͼ100 days after BMT. 2 In children the incidence of cGVHD has been reported to be lower, 3 but morbidity and mortality in patients with untreated or uncontrolled cGVHD are still significant.
Thalidomide, synthesized in 1953 and initially used as a sedative, was found to have immunosuppressive properties and has been used to treat GVHD only in recent years. Several possible mechanisms may explain the drug's immunomodulating activity including alteration of neutrophil and T cell function and reduced immunoglobulin production, but they are still incompletely clarified. Some studies suggest a synergistic effect between thalidomide and CsA. [4] [5] [6] Up to now only a limited number of children with cGVHD have been treated with thalidomide. [7] [8] [9] [10] [11] [12] We present a review of our experience with thalidomide as treatment for severe and/or refractory cGVHD in 14 children after BMT. The aim of our study was to evaluate the efficacy and toxicity of thalidomide in such young patients.
Patients and methods
Between June 1985 and December 1995, 190 children underwent allogeneic BMT at the Pediatric Hematology and BMT Unit of the University of Milan at San Gerardo Hospital in Monza and at the Pediatric BMT Unit of the University of Turin in Turin, Italy. Fourteen children (32.5%) from a total of 43 (22.6%) who developed cGVHD were treated with thalidomide at both institutions for this study.
The clinical characteristics of the patients and conditioning regimens 3, 13, 14 are shown in Table 1 . Thirteen patients received BMT from an HLA A-B and DR identical donor, 10 from a sibling and three from a matched unrelated donor (MUD). One of the 14 patients underwent BMT from the phenotypically identical mother. Three of the 14 children (cases 2, 6 and 11) underwent a second infusion of hematopoietic stem cells from the same donor at 6, 6 and 5 months after the first BMT, respectively. A second marrow infusion was performed in case 6, when the patient was already receiving thalidomide, because of poor engraftment and in cases 2 and 11 because of relapse after the first BMT. Both these latter two cases underwent a second conditioning regimen. In case 11, donor peripheral blood stem cells were used for the second infusion which was performed after achieving the third complete remission. As cases 2 and 11 had uneventful first post-BMT courses with the exception of relapse, and developed cGVHD which was treated with thalidomide after the second transplant, they have been described from the latter time-point onwards. Nine of the 14 patients received cyclosporin A (CsA) only as prophylaxis against acute GVHD, 2/14 CsA and methotrexate (MTX), 2/14 CsA, MTX and anti-thymocyte globulin (ATG) and 1/14 MTX only. 3, 15 The diagnosis and grading of cGVHD was based on clinical features according to standardized criteria; 16 only two children (cases 4 and 9) underwent intestinal biopsy which confirmed cGVHD.
Patients eligible for thalidomide treatment were those with high-risk and/or refractory cGVHD. [10] [11] [12] High-risk patients were defined as having progressive onset (acute GVHD evolving to cGVHD) and/or thrombocytopenia (р100 x 10 9 /l) at the time of diagnosis of clinical extensive cGVHD. Patients were considered to have refractory disease when they did not respond to standard therapy at optimal dosage with CsA and corticosteroids. Azathioprine (AZA) was empirically included in the primary treatment of some refractory cases as it could improve responses and decrease the disability of cGVHD 17 in spite of an increased risk of infection with a possible negative impact on survival. 2 Other eligibility criteria were: (1) no evidence of pre-existing neuropathy and (2) the ability to take oral medications. Patients' eligibility and their characteristics at the start of thalidomide are reported in Table 2 .
Thalidomide was supplied by Grunenthal GmbH (Stolberg/Rhld, Germany) as 100 mg tablets. A signed informed-consent form was obtained in all cases. The starting dose was 3-6 mg/kg/day, subsequently adjusted according to toxicity and cGVHD evolution, aiming at a target dose of 12 mg/kg/day calculated to the nearest 50 mg, in two to four divided doses, with 800 mg as daily maximum dose. Thalidomide was administered before meals to increase absorption. Thalidomide plasma levels were not monitored and adjustments were based on clinical criteria. Frequency of follow-up was determined according to clinical requirements but was carried out at least every 2 weeks. The complete disappearance of all clinical manifestations of cGVHD was classified as a complete response.
A partial response was considered when a 50% improvement in clinical and laboratory parameters (total bilirubin, pulmonary function tests) was observed and/or when cGVHD flared after tapering or discontinuing thalidomide. Patients were considered to have no response if cGVHD progressed after 1 month or failed to improve after 3 months of treatment. 12 Other current medications for GVHD were maintained and tapered after achieving control of cGVHD or because of toxicity. Thalidomide tapering in those patients who responded well did not begin until other immunosuppressive drugs had been discontinued.
Toxicity was evaluated according to WHO criteria.
Results
The median age at BMT was 8.5 years (minimum 2, maximum 19). The results of thalidomide treatment are summarized in Table 3 . One patient (case 3) who had thrombocytopenia at cGVHD diagnosis, received thalidomide only as initial primary treatment. The median length of primary cGVHD treatment (calculated from day +100) before introducing thalidomide in the other 13 patients was 219 days (minimum 38, maximum 1000). After the introduction of thalidomide, cGVHD resolved completely in six children in a median time of 2 months (minimum 1, maximum 4.5 months). Four of these six children had quiescent cGVHD. Four out of 14 patients (cases 1, 2, 6 and 7) had a partial response. In cases 1 and 2, after a slow but marked improvement, cGVHD progressed requiring further modification of the combined immunosuppressive regimen to attain sustained control. Subsequently, each attempt to reduce the thalidomide dose was followed by a 'flaring' of cGVHD. In case 6 improvement was extremely slow, but impressive on long-term continuation of thalidomide. One patient (case 7) after having achieved a partial response, developed a thrombotic thrombocytopenic microangiopathy and died on day +274. Four of the 14 patients failed to show any benefit and three of them died as a result of progressive multi-systemic cGVHD and fatal infections a few weeks after the start of thalidomide. The median maximum dose of thalidomide achieved was 5.5 mg/kg/day (minimum 3, maximum 9.5). The target dose of thalidomide was never achieved because of early onset of toxicity which did not allow dose intensification. In case 2, the initial dose was never modified because of the gradual improvement observed with no side-effects.
Eleven patients developed somnolence which resolved or became insignificant after the first 1-3 months of treatment, with the exception of one young patient (case 4) who had somnolence for the whole treatment period. Five patients suffered from marked constipation which resolved with stool softeners in four cases; constipation at end stage (case 11) could not be attributed solely to thalidomide as this patient was also receiving opioid analgesics. Peripheral neuropathy occurred in two children. One case (case 1) had clinical and neurophysiological evidence of a peripheral neuropathy 50 months after the start of thalidomide which was then reduced by 50%. After 4 months the symptoms attributable to neuropathy had disappeared. Further neurophysiological testing was not carried out owing to patient refusal. In the second case (case 3), neuropathy developed after 9 months of thalidomide treatment in a child who had had a complete response. Thalidomide was discontinued and cGVHD never reappeared, but the resolution of the neuropathy by neurophysiological testing was documented 58 months after BMT. No life-threatening or recurrent infections occurred among the partial or complete responders during thalidomide treatment, with the exception of case 1, who developed an idiophatic interstitial pneumonia which resolved 15 months after the initiation of thalidomide, and case 2 who had recurrent minor respiratory infections.
All responding patients, excluding case 7, are alive 49-111 months after BMT with a Lansky Play-Performance or a Karnofsky score of 100% with the exception of two partial responders with a Karnofsky score of 70% (case 1) and a Lansky score of 50% (case 2) who are still receiving thalidomide to maintain control of cGVHD. All children who had a complete response and one of the partial responders (case 6) discontinued all treatment and are well, with no signs of cGVHD. Among patients who failed to respond only one (case 14) is still alive with cGVHD and a Lansky score of 80%
Discussion
Chronic GVHD occurs in about 25% of children undergoing BMT. 3 Although it resolves in more than 80% of cases, some patients remain refractory to therapy (CsA, steroids, AZA) or become steroid dependent necessitating alternative treatments. In our experience thalidomide was effective, bringing about an improvement in cGVHD in most highrisk and/or refractory cases. However, a complete response was observed in only 42% of patients. This figure drops to 21% if patients with limited disease or those receiving thalidomide as sole therapy are excluded. These results are similar to those found in adult series. 10, 12 In most cases, as in other series, [9] [10] [11] [12] thalidomide was administered in combination with other immunosuppressive drugs and so the aforementioned clinical results should be considered with caution.
It has been suggested that the best responses with thalidomide can be obtained in mucocutaneous GVHD, but elegibility criteria for study entry and thalidomide dosages have varied among the limited number of clinical available studies. [7] [8] [9] [10] [11] [12] 18 Furthermore, the role of thalidomide in multisystemic cGVHD cannot be excluded. 9, 19 The best responders in our series had predominantly mucocutaneous involvement and less severe cGVHD than patients with partial responses or those who failed. Most complete responders had quiescent cGVHD.
In most cases treatment of cGVHD with thalidomide allowed discontinuation or reduction of other immunosuppressive drugs. Since it is desirable to limit the long-term use of corticosteroids in children, thalidomide may have a role in first-line therapy for cGVHD. However, the optimal dose, schedule and timing of thalidomide has not yet been defined. Drug absorption is variable and inter-patient plasma levels variations are also significant. 9 In normal volunteers the thalidomide half-life was about 8 h, 20 but basal levels seem to be maintained even on a single daily dose. 9 Data on blood levels are available only in animals and it is not known if the same levels are necessary in humans. Thalidomide dose levels have been derived from previous clinical studies and ranged in different reports from 3 to 12 mg/kg/day in one to four divided doses for up to 2-3 years. Some studies adopted a dose-adjusted schedule according to blood levels, 10, 11 aiming at a target dose of 12 mg/kg/day. We adopted the same target dose without monitoring thalidomide blood levels and adjusted the initial dose according to the clinical evaluation of GVHD control and toxicity. The onset of side-effects did not allow dose intensification in most patients. However, our patients like others, 9, 12 certainly showed a parallel sustained response on comparatively low doses, as is reported in dose-adjusted schedule studies. 10, 11 No concrete information is available on the optimal timing for starting thalidomide treatment. Whether an early introduction of thalidomide can improve efficacy in the treatment of cGVHD or whether thalidomide should really be used as first-line treatment of cGVHD, is still undefined. A potential role for thalidomide in the treatment of acute GVHD has also been claimed. 21 Side-effects occurred frequently in our series, but with the exception of two patients who developed neuropathy, they were in most cases limited to short-lasting somnolence and constipation of a mild degree. Uniquely, in one of our cases, somnolence disappeared only after drug withdrawal. Peripheral neuropathy has been reported to occur in 5% of patients treated with thalidomide for GVHD, resolving in most cases after thalidomide discontinuation in a matter of days or weeks. 10, 12 In a published pediatric series, there were no cases affected by this complication. 11 In all these studies, the thalidomide dose was much higher than the one used in our series, where neuropathy seemed to occur more frequently. In one of our cases, neuropathy was worryingly long-lasting despite drug discontinuation. Others have reported similar results with low-dose thalidomide. 9 It has been suggested that neuropathy might possibly be related to cumulative dose or duration of treatment. 22 However, one of our two cases developed neuropathy after 9 months of thalidomide, which is a shorter treatment period than many of those reported by others.
11 When neurophysiological tests have been performed to detect subclinical abnormalities, the incidence of neuropathy has been reported to range from 0.5 up to as much as 50% in patients receiving thalidomide for other diseases, and historical reports have shown that it can persist in a significant percentage of patients. 23 All patients should be carefully monitored to detect development of sensory peripheral neuropathy early on.
In conclusion, thalidomide can be effective in the treatment of cGVHD in children and allows discontinuation or diminution of other immunosuppressive agents in many cases. Patients with mucocutaneous involvement may be the best candidates for thalidomide treatment. Peripheral neuropathy is a potential risk for any treated patient. The heterogeneity in existing studies and the limited number of treated children make it difficult to draw definite conclusions about the role that thalidomide can play in the treatment of cGVHD. Prospective randomised studies should be set up to evaluate the optimal timing of thalidomide introduction, toxicity associated with the drug and the subgroups of patients that could benefit significantly from thalidomide treatment.
